Trial Profile
Phase 1 Study of TCN-202 (Human Anti-Cytomegalovirus Monoclonal Antibody) in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 May 2014
Price :
$35
*
At a glance
- Drugs TCN 202 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions
- Sponsors Theraclone Sciences
- 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 10 Sep 2013 Results were presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 2013, according to a Theraclone Sciences media release.
- 01 Aug 2013 Status changed from active, no longer recruiting to completed, according to a Theraclone Sciences media release.